Arcadia Biosciences (RKDA) Fundamental Analysis: Revenue, Earnings & Valuation

5.64 / 10

Netural

Fundamental analysis rates the company neutral (5.6/10). Strengths lie in PB‑ROE and Profit‑MV, delivering positive returns, while Cash‑MV and profit‑to‑net‑profit ratios lag. The composite fund score is 5.64, reflecting a balanced but selective outlook.

Analysis Checks(6/10)

Revenue-MV

Value-0.17

Score1/3

Weight1.81%

1M Return0.32%

Annualized return on equity (%)

Value-45.14

Score2/3

Weight12.28%

1M Return1.96%

Net profit attributable to parent company shareholders / Net profit (%)

Value100.00

Score1/3

Weight-6.19%

1M Return-1.21%

Profit-MV

Value0.40

Score3/3

Weight43.52%

1M Return6.04%

Net income-Revenue

Value0.91

Score1/3

Weight2.11%

1M Return0.40%

PB-ROE

Value-0.51

Score2/3

Weight18.28%

1M Return2.86%

Rate of return on total assets (%)

Value-25.44

Score2/3

Weight10.20%

1M Return1.69%

Annualized return on total assets (%)

Value-25.44

Score2/3

Weight10.20%

1M Return1.69%

ROE (%)

Value-45.14

Score2/3

Weight12.28%

1M Return1.96%

Cash-MV

Value-0.09

Score1/3

Weight-4.49%

1M Return-0.95%

Is RKDA fundamentally strong?

RKDA scores 5.64/10 on fundamentals and holds a Fair valuation at present. Backed by its -45.14% ROE, -48.15% net margin, -1.29 P/E ratio, 0.73 P/B ratio, and 66.92% earnings growth, these metrics solidify its Netural investment rating.